passiv
immunotherapi
exampl
use
specif
antibodi
may
repres
good
possibl
treatment
strategi
middl
east
respiratori
syndrom
coronaviru
merscov
howev
produc
largeenough
quantiti
antibodi
econom
logist
challeng
new
studi
luke
et
al
use
transchromosom
tc
bovin
produc
human
antimerscov
antibodi
show
efficaci
vitro
mous
model
merscov
infect
author
use
cattl
lack
bovin
immunoglobulin
ig
gene
instead
carri
human
artifici
chromosom
bear
gene
encod
human
ig
heavi
chain
chain
protein
bia
produc
subclass
antibodi
follow
vaccin
anim
produc
g
human
polyclon
igg
antibodi
per
month
next
author
creat
two
differ
merscov
vaccin
wholekil
jordan
strain
virion
vaccin
wkvv
alhasa
strain
spike
protein
nanoparticl
vaccin
spnv
tc
bovin
vaccin
everi
day
five
occas
wkvv
spnv
two
human
polyclon
igg
product
name
respect
purifi
hyperimmun
plasma
collect
anim
vitro
pretreat
jordan
strain
merscov
cultur
vero
kidney
epitheli
cell
markedli
reduc
virusinduc
cytopathi
impli
antibodi
neutral
merscov
antibodydepend
enhanc
infect
wherebi
antibodi
facilit
entri
virus
cell
carri
usual
entri
receptor
viru
suggest
occur
follow
use
anticov
vaccin
author
treat
jordan
strain
merscov
incub
viru
raji
cell
human
b
cell
lack
dipeptidyl
peptidas
merscov
entri
receptor
therefor
permiss
merscov
level
merscovspecif
rna
transcript
raji
cell
hour
later
increas
pretreat
either
impli
treatment
facilit
viru
entri
cell
viral
titer
lung
mice
control
limit
detect
although
mice
typic
express
resist
merscov
infect
transduct
mice
human
adenoviru
mice
confer
suscept
author
intraperiton
inject
mice
control
human
igg
hour
later
intranas
infect
merscov
day
postinfect
viral
titer
lung
mice
control
limit
detect
treatment
mice
hour
merscov
exposur
also
reduc
lung
viral
titer
day
later
limit
detect
thu
singl
treatment
effect
either
prophylact
exposur
merscov
studi
demonstr
larg
quantiti
human
merscovneutr
antibodi
rapidli
produc
tc
bovin
thu
provid
possibl
strategi
develop
passiv
immunotherapi
coronavirus
new
emerg
infecti
diseas
